New drug cocktail shows promise for tough bile duct cancer
NCT ID NCT02386397
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of the targeted drug regorafenib with chemotherapy (mGEMOX) in 66 people with advanced bile duct cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effects. This is not a cure, but aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Val d'Aurelle
Montpellier, 34298, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody boost chemotherapy for a rare bile duct cancer?
- New drug cocktail aims to tame deadly bile duct cancer
- Supercharged immune cells take on bile duct cancer in early trial
- New cocktail of drugs shows promise for bile duct cancer
- Tailored chemo doses aim to cut severe side effects in digestive cancer patients
- Immunotherapy duo takes on rare cancers